JP2018177734A - 脂質吸収促進剤 - Google Patents
脂質吸収促進剤 Download PDFInfo
- Publication number
- JP2018177734A JP2018177734A JP2017083323A JP2017083323A JP2018177734A JP 2018177734 A JP2018177734 A JP 2018177734A JP 2017083323 A JP2017083323 A JP 2017083323A JP 2017083323 A JP2017083323 A JP 2017083323A JP 2018177734 A JP2018177734 A JP 2018177734A
- Authority
- JP
- Japan
- Prior art keywords
- fat
- palmitic acid
- absorption
- infants
- fat absorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124532 absorption promoter Drugs 0.000 title claims abstract description 14
- 238000010521 absorption reaction Methods 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000003925 fat Substances 0.000 claims description 76
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 64
- 239000003921 oil Substances 0.000 claims description 44
- 235000021314 Palmitic acid Nutrition 0.000 claims description 32
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000029087 digestion Effects 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 69
- 230000000052 comparative effect Effects 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 150000004665 fatty acids Chemical class 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003623 enhancer Substances 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 125000005457 triglyceride group Chemical group 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019620 fat digestibility Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Abstract
Description
[1]β位−パルミチン酸を含んだ油脂を有効成分とする、脂肪吸収促進剤。
[2]油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、[1]に記載の脂肪吸収改善剤。
[3]脂肪の吸収を促進させる組成物を製造するための、β位−パルミチン酸を含んだ油脂の使用。
[4]油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、[3]に記載の使用。
[5]β位−パルミチン酸を含んだ油脂を用いることを特徴とする、脂肪の吸収を促進する方法。
[6]油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、[5]に記載の脂肪の吸収を促進する方法。
[7]脂肪吸収促進剤の製造に使用するための、β位−パルミチン酸を含んだ油脂。
[8]油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、[7]に記載の油脂。
[9]β位−パルミチン酸を含んだ油脂を有効成分とする脂肪吸収促進剤を含有する、乳幼児用食品。
[10]油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、[9]に記載の乳幼児用食品。
[11]β位−パルミチン酸を含んだ油脂を有効成分とする脂肪吸収促進剤を含有する、調製粉乳。
[12]油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、[11]に記載の調製粉乳。
パルミチン酸のβ位結合比率の違いが、パルミチン酸吸収率に与える影響を検討した。パルミチン酸のβ位結合比率が低い油脂、中程度の油脂、高い油脂を摂取する群を、それぞれ比較例1、比較例2、実施例1として設定した。各群が摂取する飼料の組成を表1に示した。また、表1に示した「試料油脂」の組成を調整することで、各群が摂取する試料中のパルミチン酸のβ位結合比率を調整した。各群における、主要な脂肪酸の組成、及びパルミチン酸のβ位結合比率を表2に示した。
油脂摂取後の消化時の特性を模擬的に検証することを目的として、以下の実験を行った。実施例2及び比較例3の油脂を用意した。実施例2及び比較例3の主要な脂肪酸の組成を表4に示した。実施例と比較例の油脂で大きく異なる点は、パルミチン酸のβ位への結合比率のみであり、それ以外の主要な脂肪酸組成は、ほとんど同じである。これらの実施例2及び比較例3の油脂を用いて、表5に示した組成で、人工消化反応液を調製した。調製後の人工消化反応液中の成分の濃度は、胆汁酸が20mg/mL、リパーゼが2.4mg/mL、塩化カルシウムが19mM、塩化ナトリウムが150mM、油脂が2.5%であった。なお、リパーゼは、「Lipase from porcine pancreas (Type II)」(シグマアルドリッチ社製、Cat.No.L3126)を用いた。
Claims (4)
- β位−パルミチン酸を含んだ油脂を有効成分とする、脂肪吸収促進剤。
- 油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、請求項1に記載の脂肪吸収改善剤。
- 脂肪の吸収を促進させる組成物を製造するための、β位−パルミチン酸を含んだ油脂の使用。
- 油脂の全パルミチン酸におけるβ位−パルミチン酸の比率が54%以上98%未満である、請求項3に記載の使用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017083323A JP2018177734A (ja) | 2017-04-20 | 2017-04-20 | 脂質吸収促進剤 |
TW107113298A TW201900038A (zh) | 2017-04-20 | 2018-04-19 | 脂質吸收促進劑 |
PCT/JP2018/016090 WO2018194116A1 (ja) | 2017-04-20 | 2018-04-19 | 脂質吸収促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017083323A JP2018177734A (ja) | 2017-04-20 | 2017-04-20 | 脂質吸収促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018177734A true JP2018177734A (ja) | 2018-11-15 |
JP2018177734A5 JP2018177734A5 (ja) | 2020-05-21 |
Family
ID=63855961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017083323A Pending JP2018177734A (ja) | 2017-04-20 | 2017-04-20 | 脂質吸収促進剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2018177734A (ja) |
TW (1) | TW201900038A (ja) |
WO (1) | WO2018194116A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015091228A (ja) * | 2013-10-02 | 2015-05-14 | 株式会社カネカ | 油脂組成物 |
JP2015109808A (ja) * | 2012-03-29 | 2015-06-18 | 株式会社カネカ | 油脂組成物 |
JP2016202001A (ja) * | 2013-10-02 | 2016-12-08 | 株式会社カネカ | 油脂組成物 |
-
2017
- 2017-04-20 JP JP2017083323A patent/JP2018177734A/ja active Pending
-
2018
- 2018-04-19 TW TW107113298A patent/TW201900038A/zh unknown
- 2018-04-19 WO PCT/JP2018/016090 patent/WO2018194116A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015109808A (ja) * | 2012-03-29 | 2015-06-18 | 株式会社カネカ | 油脂組成物 |
JP2015091228A (ja) * | 2013-10-02 | 2015-05-14 | 株式会社カネカ | 油脂組成物 |
JP2016202001A (ja) * | 2013-10-02 | 2016-12-08 | 株式会社カネカ | 油脂組成物 |
Non-Patent Citations (1)
Title |
---|
片岡直樹, 日本小児科学会, vol. 83(9), JPN6018021518, 1979, pages 1130 - 1145, ISSN: 0004765418 * |
Also Published As
Publication number | Publication date |
---|---|
TW201900038A (zh) | 2019-01-01 |
WO2018194116A1 (ja) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU661297B2 (en) | Microbial oil mixtures and uses thereof | |
TW200934396A (en) | Stable nutritional powder | |
EP2413718B1 (en) | Use of arachidonic acid for the reduction of the risk of insulin resistance later in life | |
RU2014101160A (ru) | Эффекты метаболического импринтинга специально разработанного липидного компонента | |
US10888104B2 (en) | Fatty acid composition and method for fortifying nutritional products with fatty acids | |
CN105188411A (zh) | 增强dha和其它脂溶性营养物的生物利用度的方法 | |
US8999926B2 (en) | Nutritional composition for infants | |
JP5144503B2 (ja) | 中鎖トリグリセリド油と組み合わせた3−hpa産生性ラクトバチルス菌株を使用して哺乳動物の免疫機能を向上させる方法 | |
TW201236578A (en) | Nutritional products comprising beta-hydroxy-beta-methylbutyrate | |
CN101321477A (zh) | 脂肪酸盐及其制备和使用方法 | |
Metzler-Zebeli | The role of dietary and microbial fatty acids in the control of inflammation in neonatal piglets | |
JPH04501114A (ja) | トリグリセリド,該トリグリセリドを含んでなる栄養組成物、および栄養物用の栄養組成物の使用 | |
CN102271652A (zh) | 含有共轭亚油酸的纳米水乳液组合物 | |
RU2489893C2 (ru) | Композиция на основе лецитина и ее применение в пище | |
JP2018177734A (ja) | 脂質吸収促進剤 | |
US20110275600A1 (en) | Methods for increasing endogenous plasmalogen levels | |
JP4684360B2 (ja) | 葉酸強化卵 | |
JP2001120189A (ja) | 反芻動物用脂肪酸給与組成物 | |
WO2020248710A1 (zh) | 一种油脂组合物及其制备方法 | |
JP5735576B2 (ja) | コエンザイムq10を含有する組成物 | |
JP2013063937A (ja) | Gip上昇抑制剤 | |
Vaquero et al. | Long‐chain fatty acid supplemented infant formula does not influence calcium and magnesium bioavailability in weanling rats | |
JPH01218547A (ja) | ビタミンd代謝産物を配合した育児用調製乳 | |
JP2516794C (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20171215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200406 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211130 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220510 |